Disease · MONDO_0022430
persistent fetal circulation syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. persistent fetal circulation syndrome. Diseases, record MONDO_0022430. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0022430
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Fetal circulation, PPHN, Persistent fetal circulation (disorder), Persistent fetal circulation syndrome (disorder), Persistent pulmonary hypertension of the newborn (disorder), congenital alveolar capillary dysplasia with misalignment of pulmonary veins, persistent fetal circulation, persistent foetal circulation, persistent pulmonary hypertension of the newborn
- Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SILDENAFIL | CHEMBL192 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ALBUTEROL | CHEMBL714 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BOSENTAN | CHEMBL957 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MAGNESIUM SULFATE | CHEMBL3989857 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ALPROSTADIL | CHEMBL495 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OMEGA-3 FATTY ACIDS | CHEMBL4298065 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| TREPROSTINIL | CHEMBL1237119 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SILDENAFIL CITRATE | CHEMBL1737 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MELATONIN | CHEMBL45 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MILRINONE | CHEMBL189 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets13
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GUCY1A1 | Soluble guanylate cyclase | 2 | Soluble guanylate cyclase activator | Unknown | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 2 | Soluble guanylate cyclase activator | Unknown | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 2 | Soluble guanylate cyclase activator | Unknown | https://conductscience.org/library/genes/2983 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 2 | Phosphodiesterase 5A inhibitor | Phase 3 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| ADRB2 | Beta-2 adrenergic receptor | 1 | Beta-2 adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| EDNRA | Endothelin receptor, ET-A/ET-B | 1 | Endothelin receptor, ET-A/ET-B antagonist | Phase 3 | https://conductscience.org/library/genes/1909 | Drugs and targets |
| EDNRB | Endothelin receptor, ET-A/ET-B | 1 | Endothelin receptor, ET-A/ET-B antagonist | Phase 3 | https://conductscience.org/library/genes/1910 | Drugs and targets |
| MTNR1A | Melatonin receptor | 1 | Melatonin receptor agonist | Unknown | https://conductscience.org/library/genes/4543 | Drugs and targets |
| MTNR1B | Melatonin receptor | 1 | Melatonin receptor agonist | Unknown | https://conductscience.org/library/genes/4544 | Drugs and targets |
| PDE3A | cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A | 1 | Phosphodiesterase 3A inhibitor | Unknown | https://conductscience.org/library/genes/5139 | Drugs and targets |
1 to 10 of 13
See all 13 targetsTrials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01720524 | A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn | Phase 3 | 59 | 2020-03-25 | Pulmonary Hypertension, Familial Persistent, of the Newborn | SILDENAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT02261883 | Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn | Phase 2 | 42 | 2024-03-05 | Persistent Pulmonary Hypertension of the Newborn | TREPROSTINIL | Its record names the disease | ClinicalTrials.gov |
| NCT06603766 | Treatment of Persistent Pulmonary Hypertension in Neonates With Nebulized Magnesium Sulfate | Phase 2/3 | 40 | 2025-02-05 | Magnesium Sulfate - PPHN | MAGNESIUM SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT01389856 | Persistent Pulmonary Hypertension of the Newborn | Phase 3 | 23 | 2015-03-23 | Persistent Pulmonary Hypertension of the Newborn | BOSENTAN | Its record names the disease | ClinicalTrials.gov |
| NCT01088997 | Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn | Not applicable | 12 | 2016-07-12 | Persistent Fetal Circulation Syndrome | MILRINONE | Its record names the disease | ClinicalTrials.gov |
| NCT01069861 | Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN) | Phase 2 | 4 | 2012-12-03 | PPHN, Persistent Pulmonary Hypertension of the Newborn, Hypoxic Respiratory Failure | SILDENAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT05527704 | the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial) | Phase 3 | 608 | TTN, Respiratory Failure, PPHN | ALBUTEROL | Its record names the disease | ClinicalTrials.gov | |
| NCT00139217 | NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn | Not applicable | 400 | Pulmonary Hypertension | NITRIC OXIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05741229 | The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns | Not applicable | 80 | Persistent Pulmonary Hypertension of the Newborn, Echocardiography, Respiratory Disease | NITROGLYCERIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07090720 | Melatonin Effects on the Left Ventricular Function in Neonates With Persistent Pulmonary Hypertension | Not applicable | 80 | Melatonin, Left Ventricular Function, Neonates, Persistent Pulmonary Hypertension | MELATONIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| IV Sildenafil vs Placebo: Number of Participants With Laboratory Abnormalities | 27 of 29 | 22 of 28 | 57 | NCT01720524 | Trial comparisons |
| IV Remodulin vs Placebo: deaths from any cause | 4 of 20 | 2 of 21 | 41 | NCT02261883 | Trial comparisons |
| IV Remodulin vs Placebo: serious adverse events | 8 of 20 | 3 of 21 | 41 | NCT02261883 | Trial comparisons |
| Nebulized Magnesium (NebMag) Group 1 vs Intravenous Magnesium (IVMag) Group 2: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT06603766 | Trial comparisons |
| Nebulized Magnesium (NebMag) Group 1 vs Intravenous Magnesium (IVMag) Group 2: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT06603766 | Trial comparisons |
| Bosentan vs Placebo: serious adverse events | 2 of 13 | 3 of 8 | 21 | NCT01389856 | Trial comparisons |
| High Dose Milrinone vs Low Dose Milrinone: serious adverse events | 0 of 7 | 0 of 5 | 12 | NCT01088997 | Trial comparisons |
Papers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0022430
GET https://conductscience.org/api/diseases/v1/MONDO_0022430/drugs